Dr. Muhammad Masab, MD

Dr. Masab practices at Virginia Oncology Associates in Elizabeth City, North Carolina.

Dr. Masab's NPI, 1336522192, was assigned on June 29, 2015. Dr. Masab holds Virginia license 0101278022.

Dr. Masab's primary practice is Virginia Oncology Associates, at 1503 N Road St, Elizabeth City, NC 27909 in Pasquotank County. The practice phone is (252) 331-2044.

Dr. Masab's primary practice is Virginia Oncology Associates in Elizabeth City, North Carolina. Dr. Masab is also affiliated with Sentara Albemarle Medical Center. The medical group on file is Virginia Oncology Associates. Dmand AI also links Dr. Masab to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Masab practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Masab's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Masab is licensed in Virginia.

CMS data shows 1,406 Medicare services from Dr. Masab across 10 procedure codes in 2024, for 303 Medicare patients. Medicare paid $63,341 for them.

CMS counts 303 Medicare patients who saw Dr. Masab in 2024. The largest group is 65 to 74, with 128 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Masab's median patient age at 69, with 60% women.

In 2024, Dr. Masab wrote 870 Medicare Part D claims for 114 patients. 75% of them were for generic drugs. CMS names the drug for 650 of them, across 25 drugs with 11 or more claims each, at $1,870,482 in total drug cost. In 2023, CMS named 42 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Masab for performance year 2024, reported through an alternative payment model (APM). Dr. Masab accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Masab as offering telehealth.

Dmand AI links 11 papers to Dr. Masab, published from 2016 to 2021. 2018 was the busiest year, with 6. The most frequent topics are Carcinoma, Non-Small-Cell Lung, Immunotherapy, Adoptive and Lung Neoplasms. Dr. Masab has published most often in Cureus. Dr. Masab's most frequent co-authors are Sorab Gupta, MD, Ena Arora, MD and Claudia Mattos Da Costa Dourado, MD.

CMS Open Payments shows 192 general payments to Dr. Masab from 45 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 88% of the total. Daiichi Sankyo Inc. paid the most, $486.